Breast cancer Posts on Medivizor

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Posted by Medivizor on Oct 24, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Posted by Medivizor on Oct 17, 2021 in Breast cancer | 0 comments

In a nutshell The authors evaluated the efficacy and safety of pyrotinib (Irene), for the treatment of HER2- positive metastatic breast cancer (MBC) in a real-world setting. The authors observed that pyrotinib was effective and well tolerated by patients. Some background Breast cancer (BC) is the most common tumor in women...

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Posted by Medivizor on Oct 16, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer (BC). The data showed that THP (taxanes + trastuzumab + pertuzumab) was the best first-line treatment, while Trastuzumab emtansine (T-DM1; Kadcycla) and...

Pyrotinib-based therapy for patients with HER2-positive advanced breast cancer

Posted by Medivizor on Oct 16, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pyrotinib (Irene)-based therapy as a treatment for patients with HER2-positive advanced breast cancer. This study concluded that pyrotinib-based therapy was safe and effective in these patients, particularly in those that received 2 or fewer therapies and received capecitabine...

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by Medivizor on Oct 9, 2021 in Breast cancer | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT). Some background Immunotherapy is a type of cancer treatment that makes use of the immune...

Evaluating the association of physical activity and sedentary behavior with fatigue, pain, and depressive symptoms among breast cancer survivors.

Posted by Medivizor on Oct 3, 2021 in Breast cancer | 0 comments

In a nutshell This study examined the association of physical activity (PA) and sedentary time (ST) with pain, fatigue, and depressive symptoms over time among survivors of breast cancer (BC). The data showed that lower ST and higher PA is associated with lower depressive symptoms in long-term survivors of BC. Some background BC is one of the most...

Evaluating the occurrence and predictors of peripheral nerve disease after breast cancer treatment.

Posted by Medivizor on Oct 3, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the occurrence and clinical predictors of peripheral neuropathy (PN; nerve damage) in long-term survivors of breast cancer (BC). The data showed that PN is an important long-term consequence of taxane-based chemotherapy in survivors of BC. Some background BC is one of the most common forms of cancer in women....

Which combination of treatments is better for HER2 positive advanced breast cancer?

Posted by Medivizor on Sep 17, 2021 in Breast cancer | 0 comments

In a nutshell This study compared two treatment regimes for HER2 positive breast cancer; pyrotinib (Irene) plus vinorelbine (Navelbine), or lapatinib (Tykerb) plus capecitabine (Xeloda). It found that pyrotinib plus vinorelbine (PV) improved survival without cancer progressing compared to lapatinib plus capecitabine (LC). Some background...

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Posted by Medivizor on Sep 12, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with...

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Posted by Medivizor on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) on health-related quality of life (HR-QoL) in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC). The data showed that this combination preserved HR-QoL in these patients. Some...

Evaluating the benefits of denosumab on bone health in women with early-stage breast cancer.

Posted by Medivizor on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the benefits of denosumab (Xgeva) on the bone health of women with early-stage breast cancer (BC). The data showed that denosumab improved bone-related outcomes in women with high-risk early-stage BC Some background BC is one of the most common forms of cancer in women. Early-stage BC is used to describe BC that is...

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Posted by Medivizor on Aug 29, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...

Breast cancer Posts on Medivizor

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Pyrotinib-based therapy for patients with HER2-positive advanced breast cancer

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Evaluating the association of physical activity and sedentary behavior with fatigue, pain, and depressive symptoms among breast cancer survivors.

Evaluating the occurrence and predictors of peripheral nerve disease after breast cancer treatment.

Which combination of treatments is better for HER2 positive advanced breast cancer?

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Evaluating the benefits of denosumab on bone health in women with early-stage breast cancer.

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Categories

Recent Posts

Archives

Breast cancer Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email